An experimental weight-loss pill is showing promising results, helping people drop 13% of their body weight in a three-month period. The results from early clinical trials were presented by Novo Nordisk — the Danish drugmaker behind Ozempic and Wegovy — at the European Association for the Study of Diabetes (EASD) annual meeting in Madrid this week.
The drug, amycretin, works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion.
Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule,” Martin Holst Lange, executive vice president and head of development at Novo Nordisk, said in a statement. “We are proud to present the phase 1 study results at EASD, showing that the mean change in percentage body weight was -13.1% with amycretin after 12 weeks of treatment.”
While Ozempic and Wegovy are administered via injection, amycretin is given as a 50-milligram oral pill. The clinical trial included participants who were obese or overweight but did not have diabetes. Those who took amycretin for 12 weeks lost more weight than those on a placebo — and higher doses led to more weight loss, according to Novo Nordisk.
Taking the pill once a day led to around 10% weight loss, and those who doubled the dose lost 13%. Another benefit the researchers highlighted is that people taking amycretin did not appear to hit a “weight loss plateau,” continuing to shed pounds as long as they took it.
“The lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment,” Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk, wrote in the study findings.
Dr. Christine Ren-Fielding, director and chief of bariatric surgery at the NYU Langone Weight Management Program, commented on the drug’s effectiveness. “GLP-1-based treatments, like Ozempic, have already shown impressive weight loss results by helping patients feel fuller for longer and reducing appetite,” she said. “Adding amylin, another hormone that plays a crucial role in regulating insulin and hunger signals, amplifies this effect.”
This “dual action” creates a more powerful tool to manage cravings and caloric intake, according to Ren-Fielding. “It’s particularly interesting because it addresses weight management through multiple physiological pathways, making it more comprehensive and potentially more effective than conventional treatments that typically focus on a single mechanism.”
The most commonly reported side effects of amycretin include gastrointestinal issues like nausea and vomiting, more so with higher doses, according to Novo Nordisk. Ren-Fielding noted that these adverse effects are not unusual with GLP-1 receptor agonists, which are known to affect gastric motility. She advised monitoring these side effects closely, as GI issues are common among patients with obesity.
“While the initial weight loss outcomes are encouraging, further studies are needed to ensure that the therapeutic benefits consistently outweigh the potential risks, especially with long-term administration,” Ren-Fielding added.
While GLP-1 based drugs — including this new experimental pill — may show promising results, Ren-Fielding emphasized that they’re “not a cure-all for obesity.” “Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” she said.
Some patients may benefit from surgical interventions, along with lifestyle changes such as regular exercise, healthy eating, and psychological support to address underlying behavioral factors. “It’s important to recognize that obesity is not just about weight loss — it’s a lifelong condition that requires ongoing management, much like any other chronic disease,” Ren-Fielding added.
The results of the study are considered preliminary, as they have not yet been published in a peer-reviewed medical journal. The researchers will continue to conduct research on amycretin in the coming months, according to Novo Nordisk.
“If further research supports these initial findings, I can envision it becoming a viable option for those struggling with obesity,” Lange said. Ren-Fielding said there is “certainly potential” for the new drug to get FDA approval, especially considering the effectiveness of GLP-1-based drugs in recent years — but confirmed that much more testing is needed.
“The current clinical trials are promising, but we need larger, long-term studies to really assess the safety and overall benefits of the drug,” she said.
For more Health articles, visit www.foxnews.com/health. Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.
